221 related articles for article (PubMed ID: 29707982)
1. Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer.
Maas M; Walz S; Stühler V; Aufderklamm S; Rausch S; Bedke J; Stenzl A; Todenhöfer T
Expert Rev Mol Diagn; 2018 May; 18(5):443-455. PubMed ID: 29707982
[TBL] [Abstract][Full Text] [Related]
2. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
3. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
[TBL] [Abstract][Full Text] [Related]
4. Clinical Decision Making in Surveillance of Non-Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers.
Zuiverloon TCM; de Jong FC; Theodorescu D
Oncology (Williston Park); 2017 Dec; 31(12):855-62. PubMed ID: 29297169
[TBL] [Abstract][Full Text] [Related]
5. Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscle-invasive bladder cancer.
Roperch JP; Grandchamp B; Desgrandchamps F; Mongiat-Artus P; Ravery V; Ouzaid I; Roupret M; Phe V; Ciofu C; Tubach F; Cussenot O; Incitti R
BMC Cancer; 2016 Sep; 16(1):704. PubMed ID: 27586786
[TBL] [Abstract][Full Text] [Related]
6. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
7. High Detection Rate for Non-Muscle-Invasive Bladder Cancer Using an Approved DNA Methylation Signature Test.
Steinbach D; Kaufmann M; Hippe J; Gajda M; Grimm MO
Clin Genitourin Cancer; 2020 Jun; 18(3):210-221. PubMed ID: 32139301
[TBL] [Abstract][Full Text] [Related]
8. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
[TBL] [Abstract][Full Text] [Related]
9. Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.
Birkenkamp-Demtröder K; Nordentoft I; Christensen E; Høyer S; Reinert T; Vang S; Borre M; Agerbæk M; Jensen JB; Ørntoft TF; Dyrskjøt L
Eur Urol; 2016 Jul; 70(1):75-82. PubMed ID: 26803478
[TBL] [Abstract][Full Text] [Related]
10. Direct quantitative detection for cell-free miR-155 in urine: a potential role in diagnosis and prognosis for non-muscle invasive bladder cancer.
Zhang X; Zhang Y; Liu X; Fang A; Wang J; Yang Y; Wang L; Du L; Wang C
Oncotarget; 2016 Jan; 7(3):3255-66. PubMed ID: 26657502
[TBL] [Abstract][Full Text] [Related]
11. A novel ultra-sensitive method for the detection of FGFR3 mutations in urine of bladder cancer patients - Design of the Urodiag® PCR kit for surveillance of patients with non-muscle-invasive bladder cancer (NMIBC).
Roperch JP; Hennion C
BMC Med Genet; 2020 May; 21(1):112. PubMed ID: 32448160
[TBL] [Abstract][Full Text] [Related]
12. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
13. Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer.
Benderska-Söder N; Ecke T; Kleinlein L; Roghmann F; Bismarck E; van Rhijn BWG; Stenzl A; Witjes JA; Todenhöfer T; Hakenberg OW; Grimm MO; Goebell PJ; Burger M; Jensen JB; Schmitz-Dräger BJ
Urol Oncol; 2024 Aug; 42(8):229-235. PubMed ID: 38403529
[TBL] [Abstract][Full Text] [Related]
14. Current approaches for identifying high-risk non-muscle invasive bladder cancer.
Sanli O; Lotan Y
Expert Rev Anticancer Ther; 2018 Mar; 18(3):223-235. PubMed ID: 29359984
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic biomarkers in non-muscle invasive bladder cancer.
Faiena I; Rosser CJ; Chamie K; Furuya H
World J Urol; 2019 Oct; 37(10):2009-2016. PubMed ID: 30467596
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus.
Schmitz-Dräger BJ; Droller M; Lokeshwar VB; Lotan Y; Hudson MA; van Rhijn BW; Marberger MJ; Fradet Y; Hemstreet GP; Malmstrom PU; Ogawa O; Karakiewicz PI; Shariat SF
Urol Int; 2015; 94(1):1-24. PubMed ID: 25501325
[TBL] [Abstract][Full Text] [Related]
17. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.
Tilki D; Burger M; Dalbagni G; Grossman HB; Hakenberg OW; Palou J; Reich O; Rouprêt M; Shariat SF; Zlotta AR
Eur Urol; 2011 Sep; 60(3):484-92. PubMed ID: 21684071
[TBL] [Abstract][Full Text] [Related]
18. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.
Christensen E; Birkenkamp-Demtröder K; Nordentoft I; Høyer S; van der Keur K; van Kessel K; Zwarthoff E; Agerbæk M; Ørntoft TF; Jensen JB; Dyrskjøt L
Eur Urol; 2017 Jun; 71(6):961-969. PubMed ID: 28069289
[TBL] [Abstract][Full Text] [Related]
19. A two-gene methylation signature for the diagnosis of bladder cancer in urine.
Bosschieter J; Nieuwenhuijzen JA; Hentschel A; van Splunter AP; Segerink LI; Vis AN; Wilting SM; Lissenberg-Witte BI; A van Moorselaar RJ; Steenbergen RD
Epigenomics; 2019 Feb; 11(3):337-347. PubMed ID: 30706728
[TBL] [Abstract][Full Text] [Related]
20. Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
Lopez-Beltran A; Cheng L; Gevaert T; Blanca A; Cimadamore A; Santoni M; Massari F; Scarpelli M; Raspollini MR; Montironi R
Expert Rev Mol Diagn; 2020 Feb; 20(2):231-243. PubMed ID: 31795775
[No Abstract] [Full Text] [Related]
[Next] [New Search]
